These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38704080)

  • 1. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
    Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
    Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma.
    Liu H; Li X; Liu W; Zhang C; Zhang S; Zhou X; Bode AM; Luo X
    Biochim Biophys Acta Mol Cell Res; 2024 Dec; 1871(8):119846. PubMed ID: 39284549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
    Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
    Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.
    Burmeister A; Stephan A; Alves Avelar LA; Müller MR; Seiwert A; Höfmann S; Fischer F; Torres-Gomez H; Hoffmann MJ; Niegisch G; Bremmer F; Petzsch P; Köhrer K; Albers P; Kurz T; Skowron MA; Nettersheim D
    Mol Cancer Ther; 2022 Nov; 21(11):1674-1688. PubMed ID: 35999659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
    Sharma NL; Groselj B; Hamdy FC; Kiltie AE
    BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
    Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
    J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
    Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
    Li Z; Liu H; Bode A; Luo X
    Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
    Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
    Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
    Meneceur S; De Vos CE; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ
    J Cell Mol Med; 2024 May; 28(9):e18342. PubMed ID: 38693852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
    Li F; Wang T; Wang Z; Chen X; Liu R
    Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
    Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
    Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells.
    Cao QF; Qian SB; Wang N; Zhang L; Wang WM; Shen HB
    Cancer Biother Radiopharm; 2015 Mar; 30(2):87-93. PubMed ID: 25760728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
    Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
    PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
    Li J; Zhang T; Yang F; He Y; Dai F; Gao D; Chen Y; Liu M; Yi Z
    Br J Pharmacol; 2015 Aug; 172(15):3817-30. PubMed ID: 25884486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
    Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
    Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.